• Scientific Advisory Board

Scientific Advisory Board

Our Scientific Advisory Board contributes to LuCE’s work in promoting new and better treatment of lung cancer.

Italy
Prof. Silvia Novello (University of Torino, Italy)
 
Novello is a professor in the thoracic oncology unit at San Luigi Hospital in Orbassano, Italy, part of the University of Turin. Prof. Novello advocates a multidisciplinary approach towards diagnosis of lung cancer and stresses the need for modernizing lung cancer research. Her research interests include thoracic malignancies, gender differences in lung cancer, experimental studies on sarcoidosis, on basic and clinical applied research on lung cancer, including pharmacogenomics. She is involved in several European clinical trials evaluating new approaches in diagnosis and lung cancer therapy.
Denmark
Prof. Jesper Holst Pedersen (University of Copenhagen, Denmark)
 
Holst Pedersen is an associate professor and consultant in thoracic surgery at Copenhagen University Hospital, Rigshospitalet. He is chairman of the surgical subcomittee of the IASLC strategic screening advisory committee. Prof. Peterson advocates for the early detection of patients with lung cancer through CT scans and calls for the EU and its member states to prepare guidelines on screening to ensure adequate follow up and management.
Netherlands
Prof. dr. Harry Groen (University of Groningen, The Netherlands)
 
With his international NELSON study, prof. Groen has shown the importance of annual screening to help early detection of lung cancer among (former) smokers. He supports LuCE’s calls on the Europe Union to increase the research funding allocated to lung cancer research and to develop guidelines on lung cancer screening and diagnosis.
Portugal
Prof. dr. António M. F. Araùjo (Centro Hospitalar do Porto and University of Porto, Portugal)
 
António M. F. Araújo is the Head of the Service of Medical Oncology at Centro Hospitalar do Porto, and is Assistant Professor at Institute of Biomedical Sciences Abel Salazar – Porto University, since Mars 2014. Member of the Portuguese National Council for Oncology, since 2013, and member of the Advisory Board of the Portuguese Health Regulatory Authority, since February 2015.